Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
In its March 2026 strategic shift, the company moved its weight-loss business to commercially available FDA-approved GLP-1s and now sells brand-name Wegovy (both the injectable pen and the new oral pill), Ozempic, and Zepbound
The risks of complications are low with this procedure and patients experience minimal down time and bruising
In clinical trials, patients using tirzepatide reported an average weight loss of up to 20% of their body weight over a year
Why Choose Pure Med Spa Chicago for Semaglutide Treatments
Many patients experience an average weight loss of 10% to 18% of their starting body weight, and some lose 15% to 21% of their body weight over 68 weeks, depending in part on starting weight
People significantly overweight will not achieve meaningful results from localized fat dissolving
US$ 27.27
US$ 22.58
US$ 22.24
US$ 23.06
US$ 22.66
